Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Retained Earnings came in at -$14.8 billion in Q1 2026, down 109.12% year-on-year from $162.6 billion in Q1 2025, and down 108.78% quarter-over-quarter from $169.0 billion in Q4 2025.

Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Retained Earnings across 18 years of filings, most recently posting -$14.8 billion for Q1 2026.

  • Retained Earnings for Q1 2026 came in at -$14.8 billion, down 109.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.8 billion (down 109.12% YoY), and the FY2025 annual result was $169.0 billion, up 8.46% from the prior year.
  • Retained Earnings came in at -$14.8 billion for Q1 2026 at Johnson & Johnson, down from $169.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $169.0 billion in Q4 2025 to a low of -$15.3 billion in Q4 2022.
  • The 5-year median for Retained Earnings is $56.6 billion (2022), against an average of $65.4 billion.
  • Across the five-year window, Retained Earnings tumbled 111.52% in 2022 and soared 1343.64% in 2024, its largest moves.
  • Johnson & Johnson's Retained Earnings stood at -$15.3 billion in 2022, then increased by 18.08% to -$12.5 billion in 2023, then jumped by 1343.64% to $155.8 billion in 2024, then advanced by 8.46% to $169.0 billion in 2025, then slumped by 108.78% to -$14.8 billion in 2026.
  • The last three Retained Earnings figures came in at -$14.8 billion (Q1 2026), $169.0 billion (Q4 2025), and -$15.2 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 1.90 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 29.51 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -14.83 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -17.87 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 66.72 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -190.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 78.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -7.20 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -1.37 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 -14.83 Bn
Dec 28, 2025 168.98 Bn
Sep 28, 2025 -15.24 Bn
Jun 29, 2025 -14.31 Bn
Mar 30, 2025 162.64 Bn
Dec 29, 2024 155.79 Bn
Sep 29, 2024 -12.52 Bn
Jun 30, 2024 -11.25 Bn
Mar 31, 2024 153.38 Bn
Dec 31, 2023 -12.53 Bn
Oct 1, 2023 152.54 Bn
Jul 2, 2023 129.38 Bn
Apr 2, 2023 124.56 Bn
Jan 1, 2023 128.35 Bn
Oct 2, 2022 -15.29 Bn
Jul 3, 2022 -13.84 Bn
Apr 3, 2022 124.38 Bn
Jan 2, 2022 -13.06 Bn
Oct 3, 2021 -15.42 Bn
Jul 4, 2021 120.15 Bn